Literature DB >> 11372767

Predictive values of coagulation/fibrinolysis parameters for the termination of pregnancy complicated by severe preeclampsia.

T Kobayashi1, N Tokunaga, M Sugimura, N Kanayama, T Terao.   

Abstract

We investigated coagulation/fibrinolysis parameters for significant differences between patients with early-onset severe preeclampsia (< 32 weeks gestation, wG) and those with late-onset severe preeclampsia (> or = 32 wG). A decrease in antithrombin (AT), protein C (PC), and free protein S (PS) activities and an increase in plasmin-alpha2-plasmin inhibitor complex (PIC), thrombin-antithrombin complex (TAT), and FDP D-dimer (D-dimer) were observed. However, there were no statistical differences between the two groups. Once preeclampsia occurred and it developed severe, the changes in coagulation/fibrinolysis parameters became more severe in spite of early-onset preeclampsia or late-onset preeclampsia. We also investigated coagulation/fibrinolysis abnormalities in 101 patients with severe preeclampsia. A significant increase in WBC, RBC, Hb, Ht, TAT, PIC, and D-dimer and a significant decrease in platelet (Plt) counts and AT activity were observed. deltaPlt (the difference between platelet counts in early gestation and before delivery) was -5.0 x 10(4)/microL in cases with severe preeclampsia. Among patients with severe preeclampsia, coagulation/fibrinolysis changes before delivery were typical for patients with cesarean section compared with those with successful vaginal delivery. These facts suggest that an excessive hypercoagulable state is associated with the termination of pregnancy resulting from the aggravation of preeclampsia. From the viewpoint of coagulation/fibrinolysis changes, the termination of pregnancy could be recommended when the levels of parameters exceed the following values; deltaPlt > -6.0 x 10(4) microL, D-dimer > 4 microg/mL, AT activity < 79%, TAT > 26 ng/mL, and PIC > 1.2 microg/mL. Particularly, deltaPlt and D-dimer are useful bedside predictive markers in order to decide the optimal time for the termination of pregnancy in patients with severe preeclampsia.

Entities:  

Mesh:

Year:  2001        PMID: 11372767     DOI: 10.1055/s-2001-14072

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  7 in total

Review 1.  Role of fibrin D-dimer testing in emergency medicine.

Authors:  A Wakai; A Gleeson; D Winter
Journal:  Emerg Med J       Date:  2003-07       Impact factor: 2.740

2.  D-dimer for the diagnosis of acute venous thromboembolism in the emergency department: a Janus-face marker.

Authors:  Roberto Manfredini
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

3.  Is D-dimer a predictor of strangulated intestinal hernia?

Authors:  Gokhan Icoz; Ozer Makay; Murat Sozbilen; Baris Gurcu; Cemil Caliskan; Ozgur Firat; Zahide Kurt; Sinan Ersin
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

4.  Thrombin activatable fibrinolysis inhibitor in preeclampsia and gestational hypertension throughout the gestation.

Authors:  Yinghong Zhang; Yu Hu; Tao Guo; Wenning Wei; Xiaoping Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-05-15

Review 5.  Pre-eclampsia part 1: current understanding of its pathophysiology.

Authors:  Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Lami Yeo; Roberto Romero
Journal:  Nat Rev Nephrol       Date:  2014-07-08       Impact factor: 28.314

6.  The Diagnostic Efficacy of Thrombelastography (TEG) in Patients with Preeclampsia and its Association with Blood Coagulation.

Authors:  He Lidan; Wu Jianbo; Gao Liqin; Hu Jifen; Lu Lin; Wu Xiuyan
Journal:  Open Life Sci       Date:  2019-07-22       Impact factor: 0.938

7.  The association of antenatal D-dimer and fibrinogen with postpartum hemorrhage and intrauterine growth restriction in preeclampsia.

Authors:  Hailing Shao; Shichu Gao; Dongru Dai; Xiaomin Zhao; Ying Hua; Huijun Yu
Journal:  BMC Pregnancy Childbirth       Date:  2021-09-05       Impact factor: 3.007

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.